CA1155392A - Procede de clarification du serum et du plasma - Google Patents

Procede de clarification du serum et du plasma

Info

Publication number: CA1155392A
Authority: CA; Canada
Prior art keywords: serum; resin; adjusted; plasma; sera
Prior art date: 1980-06-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000378563A

Other languages

English (en)

Inventor

Mary D. Du Pont

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

EIDP Inc

Original Assignee

EI Du Pont de Nemours and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-06-02

Filing date

1981-05-28

Publication date

1983-10-18

1981-05-28 Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co

1983-10-18 Application granted granted Critical

1983-10-18 Publication of CA1155392A publication Critical patent/CA1155392A/fr

Status Expired legal-status Critical Current

Links

210000002966 serum Anatomy 0.000 title claims abstract description 91
238000000034 method Methods 0.000 title claims abstract description 41
230000008569 process Effects 0.000 title claims abstract description 25
238000005352 clarification Methods 0.000 title abstract description 3
230000000694 effects Effects 0.000 claims abstract description 27
108090000790 Enzymes Proteins 0.000 claims abstract description 26
102000004190 Enzymes Human genes 0.000 claims abstract description 26
239000011347 resin Substances 0.000 claims description 40
229920005989 resin Polymers 0.000 claims description 40
238000002156 mixing Methods 0.000 claims description 13
150000001768 cations Chemical class 0.000 claims description 11
150000001450 anions Chemical class 0.000 claims description 10
230000002829 reductive effect Effects 0.000 claims description 10
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 9
239000003456 ion exchange resin Substances 0.000 claims description 9
229920003303 ion-exchange polymer Polymers 0.000 claims description 9
102000004420 Creatine Kinase Human genes 0.000 claims description 8
108010042126 Creatine kinase Proteins 0.000 claims description 8
230000002255 enzymatic effect Effects 0.000 claims description 8
239000006228 supernatant Substances 0.000 claims description 8
239000003792 electrolyte Substances 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
238000000926 separation method Methods 0.000 claims description 3
230000006872 improvement Effects 0.000 claims description 2
239000002244 precipitate Substances 0.000 claims description 2
102000004895 Lipoproteins Human genes 0.000 abstract description 19
108090001030 Lipoproteins Proteins 0.000 abstract description 19
239000000463 material Substances 0.000 abstract description 14
238000004925 denaturation Methods 0.000 abstract description 11
230000036425 denaturation Effects 0.000 abstract description 11
238000001556 precipitation Methods 0.000 abstract description 4
238000004458 analytical method Methods 0.000 abstract description 3
238000010979 pH adjustment Methods 0.000 abstract description 3
238000000149 argon plasma sintering Methods 0.000 abstract description 2
230000003247 decreasing effect Effects 0.000 abstract description 2
238000002242 deionisation method Methods 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
229940088598 enzyme Drugs 0.000 description 22
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000003729 cation exchange resin Substances 0.000 description 5
230000035602 clotting Effects 0.000 description 5
229920000669 heparin Polymers 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
108010044467 Isoenzymes Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
229960002897 heparin Drugs 0.000 description 4
238000005342 ion exchange Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000004448 titration Methods 0.000 description 4
206010053567 Coagulopathies Diseases 0.000 description 3
239000003957 anion exchange resin Substances 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
230000001351 cycling effect Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
240000007930 Oxalis acetosella Species 0.000 description 2
235000008098 Oxalis acetosella Nutrition 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
238000010908 decantation Methods 0.000 description 2
229910003460 diamond Inorganic materials 0.000 description 2
239000010432 diamond Substances 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000020477 pH reduction Effects 0.000 description 2
229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000005086 pumping Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
230000004913 activation Effects 0.000 description 1
235000016127 added sugars Nutrition 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
239000003507 refrigerant Substances 0.000 description 1
239000012508 resin bead Substances 0.000 description 1
238000005185 salting out Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
238000010257 thawing Methods 0.000 description 1
HLCHESOMJVGDSJ-UHFFFAOYSA-N thiq Chemical compound C1=CC(Cl)=CC=C1CC(C(=O)N1CCC(CN2N=CN=C2)(CC1)C1CCCCC1)NC(=O)C1NCC2=CC=CC=C2C1 HLCHESOMJVGDSJ-UHFFFAOYSA-N 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1

Landscapes

Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA000378563A 1980-06-02 1981-05-28 Procede de clarification du serum et du plasma Expired CA1155392A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15522080A	1980-06-02	1980-06-02
US155,220		1980-06-02

Publications (1)

Publication Number	Publication Date
CA1155392A true CA1155392A (fr)	1983-10-18

Family

ID=22554546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000378563A Expired CA1155392A (fr)	1980-06-02	1981-05-28	Procede de clarification du serum et du plasma

Country Status (1)

Country	Link
CA (1)	CA1155392A (fr)

1981
- 1981-05-28 CA CA000378563A patent/CA1155392A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2000-10-18	MKEX	Expiry

Publication	Publication Date	Title
US4264471A (en)	1981-04-28	Serum and plasma clarification process
Abildgaard et al.	1970	Assay of progressive antithrombin in plasma
US4483922A (en)	1984-11-20	Inactivation of enzymes
Keay et al.	1970	Proteases of the genus Bacillus. I. Neutral proteases
Laskowski	1955	[2] Chymotrypsinogens and chymotrypsins
US4290774A (en)	1981-09-22	Purification of lipoprotein cholesterol for use as a cholesterol reference material
US5358853A (en)	1994-10-25	Liquid thromboplastin reagent
Spring et al.	1971	The purification and characterization of Escherichia coli enolase
EP0359201B1 (fr)	1993-03-03	Procédé pour stabiliser des facteurs de coagulation sanguine
Masson et al.	1981	Combined enzymic-Jaffé method for determination of creatinine in serum.
Young et al.	1958	Some physical and chemical properties of crystalline α-glycerophosphate dehydrogenase
Putnins et al.	1975	Colorimetric determination of inorganic pyrophosphate by a manual or automated method
Abildgaard	1967	Inhibition of the thrombin-fibrinogen reaction by antithrombin III, studied by N-terminal analysis
US4216117A (en)	1980-08-05	Lipoprotein diluent or solution and method useful in the preparation of assay reference materials
Dissing	1987	Immunochemical characterization of human red cell acid phosphatase isozymes
Uszynski et al.	1971	Separation and characterization of two fibrinolytic inhibitors from human placenta
Pedersen	1970	Determination of calcium fractions of serum. III. Ionized calcium in ultrafiltrates of normal serum and examination of pertinent variables
DANG DAI et al.	1968	Purification and properties of l‐6‐hydroxynicotine oxidase
Blair et al.	1966	Assay and purification of (+)-citramalate hydro-lyase components from Clostridium tetanomorphum
CA1155392A (fr)	1983-10-18	Procede de clarification du serum et du plasma
Tüchsen et al.	1977	Kinetic properties of subtilisin type Carlsberg in the crystalline state
WO1983004105A1 (fr)	1983-11-24	Analyse de la coagulation du sang et reactif pour une telle analyse
Hayashi et al.	1969	Yeast Pro-proteinase C Part II. Isolation and Some Physicochemical Properties
US3864085A (en)	1975-02-04	Glutathione reagent and test method
Fischer et al.	1971	Aspartate aminotransferase (GOT) from young and old human erythrocytes